Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Lai-Shan Tam, Carlo Salvarani, Tae-Hwan Kim, Alan Solinger, Yakov Datsenko, Chandrasena Pamulapati, Sudha Visvanathan, David B Hall, Stella Aslanyan, Paul Scholl, Steven J Padula

137 Citationer (Scopus)
41 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab

Kemiske forbindelser